Loading patent…
OwnerBarry M. Bernstein, Sandeep Dutta +7inventors
InventorsBarry M. Bernstein, Sandeep Dutta, Wei Liu, Thomas J. Podsadecki, Andrew L. Campbell, Rajeev M. Menon, Chih-Wei Lin, Tianli Wang, Walid M. Awni
Estimating the term…
The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
A method for treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient, wherein neither interferon nor ribavirin are administered to said patient during said treatment, and said treatment lasts for 8, 9, 10, 11 or 12 weeks, and wherein said at least two DAAs comprise:
Dependencies are inferred from the claim text.